VT
VistaGen Therapeutics, Inc.
VTGN · NASDAQ
$0.24 -2.52% (-$0.01)
1M -12.49%
Market Cap $10.5M
P/E Ratio -
Div. Yield -
ROE 152.59%
Bulios Fair Price
$0.28
18.9% upside
Current Price
$0.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VTGN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
72 /100
Cheap P/S 4.18x
P/B 0.43x
P/E N/A
Growth
100 /100
Growing Book val. growth 43.26%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 84.57%
Net margin 2,702.64%
Op. margin 2,784.33%
Quality
1 /100
Poor ROIC 275.77%
ROE 152.59%
ROA 189.22%
Debt
100 /100
Low Debt/Equity 0.03x
Current ratio 3.07x
Int. coverage N/A
Stability
23 /100
Unstable Beta 0.39x
Rev. volatility 316.42%
EPS volatility 53.04%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VTGN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Shawn K. Singh
Employees
41
Headquarters
South San Francisco
Upcoming events
12 NOV
Earnings
Upcoming earnings report